To allow analysis for the several TAB and ASC subpopulations within individual tumor samples, we included into this comparison tumor samples with only ≥50 B cell counts as determined by CD20- and/or CD19-immunoreactivity (for sample numbers see legend Figure 4). This evidence concerns the gene CD19 and neoplasm.